KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Finished Goods (2017 - 2021)

Aquestive Therapeutics (AQST) has 4 years of Finished Goods data on record, last reported at $1.0 million in Q1 2021.

  • For Q1 2021, Finished Goods rose 42.8% year-over-year to $1.0 million; the TTM value through Mar 2021 reached $1.0 million, up 42.8%, while the annual FY2020 figure was $544000.0, 4.82% up from the prior year.
  • Finished Goods reached $1.0 million in Q1 2021 per AQST's latest filing, up from $544000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $1.3 million in Q2 2018 and bottomed at $519000.0 in Q4 2019.
  • Average Finished Goods over 4 years is $949666.7, with a median of $1.0 million recorded in 2019.
  • Peak YoY movement for Finished Goods: tumbled 56.13% in 2019, then surged 42.8% in 2021.
  • A 4-year view of Finished Goods shows it stood at $1.2 million in 2018, then crashed by 56.13% to $519000.0 in 2019, then increased by 4.82% to $544000.0 in 2020, then surged by 84.01% to $1.0 million in 2021.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $1.0 million in Q1 2021, $544000.0 in Q4 2020, and $858000.0 in Q3 2020.